| Aug 29 |
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
|
| Aug 19 |
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
|
| Aug 18 |
Jefferies Predicts up to 270% Rally for These 2 ‘Strong Buy’ Stocks
|
| Aug 13 |
Inozyme draws Buy at Jefferies on rare disease opportunity
|
| Aug 11 |
Institutional owners may consider drastic measures as Inozyme Pharma, Inc.'s (NASDAQ:INZY) recent US$49m drop adds to long-term losses
|
| Aug 6 |
Inozyme Pharma GAAP EPS of -$0.44
|
| Aug 6 |
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
|
| Jul 30 |
Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion
|
| Jul 25 |
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
|
| Jul 2 |
Inozyme gets Fast Track status for candidate for rare calcification condition
|
